Aegerion price target raised to $30 from $19 at Deutsche Bank

theflyonthewall.com

Deutsche Bank raised its price target for shares of Aegerion after an FDA panel recommended approval of Lomitapide. The firm believes the drug will be approved and keeps a Buy rating on the stock.

Rates

View Comments (0)